Biogen, Inc. (BIIB)
$206.20
1.98 (0.97%)
BIIB Stock Quote Delayed 30 Minutes
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down
Drug-making giant Biogen is in the green today after announcing CEO Michel Vounatsos is stepping down from the role.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
30.31B
PE Ratio
21.11
EPS
9.77
Volume (Avg. Vol.)
1.01M
Day's Range
$203.13 - $207.36
52-Week Range
$187.16 - $468.55
Dividend & Yield
N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! Let's get this party started with a dive into the biggest pre-market stock movers to watch for Wednesday!
4 Top Stock Trades for Friday: Ethereum, NIO, BIIB, BABA
Nio, Ethereum, Biogen and Alibaba were our top stock trades for Friday. Let's take a look at how the charts are setting up now.
BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today
There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders.
Biogen: Does Aduhelm Make it the Next Dendreon?
Aduhelm was approved by the FDA, priced at $56,000/year, but it isn't a cure for Alzheimer's.
BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today
BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses.
New Alzheimer’s Treatment Is A Huge Catalyst for Biogen
BIIB stock was boosted when its Alzheimer's drug was approved. The company's strong financials can sustain the stock's growth.
BIIB Stock: 9 Things to Know About Biogen’s Alzheimer Drug Approval Controversy
Biogen (BIIB) stock is dipping lower today on the additional controversy surrounding the approval of its Alzheimer’s drug, Aduhelm.
Biogen Gets an Unearned Rip on an Unproven Drug
Critics charge the FDA has been compromised and approved Biogen's Alzheimer's drug before it is proven to work.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Investors scrutinized updates to the Colonial Pipeline saga and bet on meme stocks.
4 Top Stock Trades for Tuesday: Bitcoin, BIIB, YETI, COUP
Bitcoin, Biogen, Yeti and Coupa were our top stock trades for Tuesday. Let's take a look at the charts and see how these names are looking.
BIIB Stock Alert: The Huge FDA News That Has Biogen Investors Smiling
Shares of BIIB stock were up to start the day on Monday after the FDA approved the firm's experimental drug to fight Alzheimer’s disease.
14 AI Stocks to Stay Away From
Whether in transportation, manufacturing or healthcare, don't touch any of these 14 AI-related stocks with a 10-foot pole. Here's why.
